StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ADMA Biologics's operating cash flow for the twelve months ending Jun 30, 2026 was $136.72M, up 78.2% year over year. For fiscal 2025 it was $50.40M, down 57.5% from the year before. The highest annual figure on record is $118.67M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$50.40M-57.5%
FY2024Dec 31, 2024$118.67M+1248.5%
FY2023Dec 31, 2023$8.80M–
FY2022Dec 31, 2022-$59.51M–
FY2021Dec 31, 2021-$112.37M–
FY2020Dec 31, 2020-$102.00M–
FY2019Dec 31, 2019-$76.19M–
FY2018Dec 31, 2018-$62.68M–
FY2017Dec 31, 2017-$37.27M–
FY2016Dec 31, 2016-$18.27M–
FY2015Dec 31, 2015-$15.42M–
FY2014Dec 31, 2014-$14.70M–
FY2013Dec 31, 2013-$10.89M–
FY2012Dec 31, 2012-$6.90M–
FY2011Dec 31, 2011-$1.43M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.54M+39.7%
Q1 FY2026Mar 31, 2026$58.25M–
Q4 FY2025Dec 31, 2025$35.64M-29.0%
Q3 FY2025Sep 30, 2025$13.29M-46.9%
Q2 FY2025Jun 30, 2025$21.14M-53.7%
Q1 FY2025Mar 31, 2025-$19.68M–
Q4 FY2024Dec 31, 2024$50.22M+185.4%
Q3 FY2024Sep 30, 2024$25.03M+108.8%
Q2 FY2024Jun 30, 2024$45.65M–
Q1 FY2024Mar 31, 2024-$2.22M–
Q4 FY2023Dec 31, 2023$17.60M–
Q3 FY2023Sep 30, 2023$11.99M–
Q2 FY2023Jun 30, 2023-$6.06M–
Q1 FY2023Mar 31, 2023-$14.72M–
Q4 FY2022Dec 31, 2022-$7.38M–
Q3 FY2022Sep 30, 2022-$13.28M–
Q2 FY2022Jun 30, 2022-$12.83M–
Q1 FY2022Mar 31, 2022-$26.01M–
Q4 FY2021Dec 31, 2021-$33.47M–
Q3 FY2021Sep 30, 2021-$13.41M–
Q2 FY2021Jun 30, 2021-$32.26M–
Q1 FY2021Mar 31, 2021-$33.23M–
Q4 FY2020Dec 31, 2020-$32.22M–
Q3 FY2020Sep 30, 2020-$23.85M–
Q2 FY2020Jun 30, 2020-$21.28M–
Q1 FY2020Mar 31, 2020-$24.65M–
Q4 FY2019Dec 31, 2019-$19.65M–
Q3 FY2019Sep 30, 2019-$23.63M–
Q2 FY2019Jun 30, 2019-$18.62M–
Q1 FY2019Mar 31, 2019-$14.29M–
Q4 FY2018Dec 31, 2018-$18.79M–
Q3 FY2018Sep 30, 2018-$12.54M–
Q2 FY2018Jun 30, 2018-$14.91M–
Q1 FY2018Mar 31, 2018-$16.43M–
Q4 FY2017Dec 31, 2017-$13.36M–
Q3 FY2017Sep 30, 2017-$9.74M–
Q2 FY2017Jun 30, 2017-$8.78M–
Q1 FY2017Mar 31, 2017-$5.40M–
Q4 FY2016Dec 31, 2016-$3.61M–
Q3 FY2016Sep 30, 2016-$4.68M–

More ADMA Biologics figures

See a number that looks wrong?